Press Room

AAPS 2020

Start
Sunday, October 25, 2020 - 00:00
End
Thursday, November 05, 2020 - 00:00
Location: online
Booth Number: Virtual Gathering
Virtual Stand for AAPS 2020  | Hovione

At Hovione, your Drug Development success is our matter. Discover how our science and technologies can help you.

 

As a fully integrated CDMO and leader in pharmaceutical spray drying, we offer to your project:

  • The best scale-up science 
  • The most up-to-date technologies and methodologies
  • Multidisciplinary experienced teams
  • State-of-the-art facilities 
  • and growing capacity to help your projects succeed

 

Join Hovione Scientists virtually at 2020 AAPS PharmSci360 and find out more about the latest research and innovations.

 



Scientific Research POSTERS:

 

Mastering Chemical Reactions on API Synthesis with Quantum Mechanics

Luís Sobral, MS

best poster abastract award seal | Hovione

 

The American Association of Pharmaceutical Scientists

Board of Directors has awarded this poster

with a 2020 AAPS Best Abstract.



 

Other Posters

Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Aerodynamic Performance

Patrícia Henriques, MS

Benchmarking Formulation and Process Approaches to Poorly Flowing Spray Dried Dispersions for Downstream Processing

Slavomíra Doktorovová, PhD

Establishing a Proactive Behavior Through Method Lifecycle: Method Performance Verification Contribution

Lúcia Volta e Sousa, PhD 

 

 

“Rapid Fire” PRESENTATIONS

Oct. 27 | 4:15 - 4:30 PM EST | Manufacturing and Analytical Characterization 

Material Sparing Approaches for Right First-time Fast Track Tablet Development

Slavomíra Doktorovová, PhD

Nov. 3 | 9:15 - 9:30 PM EST | Formulation and Delivery  

Universal-Low-Dosage DPI Platform for Delivery of Small Molecules and Biopharmaceuticals

Claudia Moura, PhD

 

 

If you have a drug development challenge, schedule a meeting with us.

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026